Claims

1. Compound of the formula



(I),

in which

R^1 represents methyl, ethyl, difluoromethyl or trifluoromethyl,

R^2 represents hydrogen, methyl, difluoromethyl or trifluoromethyl,

or

R^1 and R^2 together with the carbon atoms to which they are attached form a cyclobutyl ring,

R^3 represents methyl, ethyl or n-propyl,

where methyl may be substituted with one substituent selected from the group consisting of cyclopropyl, cyclobutyl, oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-2-yl, tetrahydro-2H-pyran-2-yl, tetrahydro-2H-pyran-4-yl and 1,4-dioxan-2-yl,

where oxetan-2-yl, tetrahydrofuran-2-yl, tetrahydro-2H-pyran-2-yl and 1,4-dioxan-2-yl may be substituted by 1 to 2 substituents independently of one another selected from the group consisting of fluorine and methyl,

or

where methyl may be substituted with one substituent of the group of the formula



where

* is the attachment site to the methyl group,

R^9 represents methyl, ethyl, iso-propyl, cyclopropyl, difluoromethyl or trifluoromethyl,

R^{10} represents methyl or difluoromethyl,

and

where ethyl may be substituted with one substituent selected from the group consisting of methoxy, ethoxy, iso-propoxy, tert-butoxy, difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, cyclopropyloxy and cyclobutyloxy,

where cyclopropyloxy and cyclobutyloxy may be substituted with one substituent selected from the group consisting of fluorine and methyl,

R^4 represents hydrogen,

R^5 represents a group of the formula



where

\# is the attachment site to the nitrogen atom,

R^{11} represents hydrogen or fluorine,

R^{12} represents methyl, difluoromethyl or trifluoromethyl,

R^{13} represents methyl, difluoromethyl or trifluoromethyl,

R^{14} represents hydrogen or methyl,

R^{15} represents hydrogen or methyl,

R^{16} represents hydrogen or methyl,

R^{17} represents hydrogen or methyl,

R^6, R^7 and R^8 represent the following:

R^6 represents hydrogen, fluorine or chlorine,

R^7 represents hydrogen,

R^8 represents hydrogen,

or

R^6 represents hydrogen,

R^7 represents fluorine or chlorine,

R^8 represents hydrogen,

or

R^6 represents hydrogen,

R^7 represents hydrogen,

R^8 represents fluorine,

or one of the salts thereof, solvates thereof or solvates of the salts thereof.

2. Compound according to Claim 1, characterized in that

R^1 represents methyl, ethyl or trifluoromethyl,

R^2 represents hydrogen or methyl,

or

R^1 and R^2 together with the carbon atoms to which they are attached form a cyclobutyl ring,

R^3 represents methyl, ethyl or n-propyl,

where methyl may be substituted with one substituent selected from the group consisting of cyclobutyl, tetrahydrofuran-2-yl, tetrahydro-2H-pyran-2-yl and 1,4-dioxan-2-yl,

where tetrahydrofuran-2-yl may be substituted by 1 to 2 substituents methyl,

or

where methyl may be substituted with one substituent of the group of the formula



where

* is the attachment site to the methyl group,

R^9 represents methyl, cyclopropyl, difluoromethyl or trifluoromethyl,

R^{10} represents methyl or difluoromethyl,

and

where ethyl may be substituted with one substituent selected from the group consisting of methoxy, iso-propoxy, tert-butoxy, difluoromethoxy, trifluoromethoxy, 2,2-difluoroethoxy, cyclopropyloxy and cyclobutyloxy,

where cyclopropyloxy and cyclobutyloxy may be substituted with one substituent selected from the group consisting of fluorine and methyl,

R^4 represents hydrogen,

R^5 represents a group of the formula



where

is the attachment site to the nitrogen atom,

R^{11} represents hydrogen or fluorine,

R^{12} represents difluoromethyl or trifluoromethyl,

R^{13} represents methyl,

R^{14} represents hydrogen or methyl,

R^{15} represents hydrogen or methyl,

R^{16} represents hydrogen,

R^{17} represents hydrogen,

R^6, R^7 and R^8 represent the following:

R^6 represents hydrogen, fluorine or chlorine,

R^7 represents hydrogen,

R^8 represents hydrogen,

or one of the salts thereof, solvates thereof or solvates of the salts thereof.

3. Compound according to Claim 1 or 2, characterized in that

R^1 represents methyl or trifluoromethyl,

R^2 represents hydrogen,

R^3 represents methyl,

where methyl is substituted with one substituent of the group of the formula



where

* is the attachment site to the methyl group,

R^9 represents methyl,

R^{10} represents methyl or difluoromethyl,

R^4 represents hydrogen,

R^5 represents a group of the formula



where

is the attachment site to the nitrogen atom,

R^{11} represents hydrogen,

R^6, R^7 and R^8 represent the following:

R^6 represents hydrogen or fluorine,

R^7 represents hydrogen,

R^8 represents hydrogen,

or one of the salts thereof, solvates thereof or solvates of the salts thereof.

4. Compound according to any of Claims 1 to 3, characterized in that it has the formula (Ia)



(Ia),

in which R^1, R^2, R^3, R^4, R^5, R^6, R^7 and R^8 are as defined in Claims 1 to 3.

5. 4-({(2*S*,4*S*)-2-[(7*R*)-11-Chloro-2-oxo-7-(trifluoromethyl)-2,6,7,8-tetrahydro-3*H*-[3]benzoxocino[2,1-c]pyridin-3-yl]-4-methoxy-pentanoyl}amino)benzamide (single stereoisomer) according to Claim 1 of the formula below



or one of the salts thereof, solvates thereof or solvates of the salts thereof.

6. 4-({(2*S*,4*S*)-2-[(7*R*)-11-Chloro-2-oxo-7-(trifluoromethyl)-2,6,7,8-tetrahydro-3*H*-[3]benzoxocino[2,1-c]pyridin-3-yl]-4-methoxy-pentanoyl}amino)benzamide (single stereoisomer) according to Claim 5 of the formula below



.

7. Process for preparing a compound of the formula (I) or one of the salts thereof, solvates thereof or solvates of the salts thereof according to Claim 1, characterized in that

[A] a compound of the formula



(II),

in which

R^1, R^2, R^3, R^6, R^7 and R^8 are as defined in claim 1,

is reacted with a compound of the formula



(III),

in which

R^4 and R^5 are as defined in claim 1,

in the presence of a dehydrating agent to give a compound of the formula (I)

or

[B] a compound of the formula (II) is converted in a one-pot reaction to the acid chloride of the compound of the formula (II) and then the acid chloride is reacted with a compound of the formula (III) to give a compound of the formula (I)

or

[C] a compound of the formula



(IV),

in which

R^1, R^2, R^6, R^7 and R^8 are as defined in claim 1,

is reacted with a compound of the formula



(V),

in which

X^1 represents bromine, iodine or trifluoromethane-sulfonyloxy,

in the presence of a base to give a compound of the formula (I).

8. Compound according to any of Claims 1 to 6 for use in the treatment and/or prophylaxis of diseases.

~~9. Use of a compound according to any of Claims 1 to 6 for producing a medicament for the treatment and/or prophylaxis of diseases.~~

~~10~~9. Use of a compound according to any of Claims 1 to 6 for producing a medicament for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders.

~~11~~10. Use of a compound according to any of Claims 1 to 6 for producing a medicament for the treatment and/or prophylaxis of disorders in the coronary arteries of the heart, such as acute coronary syndrome (ACS), myocardial infarction with ST segment elevation (STEMI) and without ST segment elevation (non-STEMI), stable angina pectoris, unstable angina pectoris, stent thrombosis, reocclusions and restenoses after coronary interventions such as angioplasty, stent implantation or aortocoronary bypass, disorders in the cerebrovascular arteries, such as transitory ischaemic attacks (TIA), ischemic strokes including cardioembolic strokes, such as strokes due to atrial fibrillation, non-cardioembolic strokes, such as lacunar stroke, strokes due to large or small artery diseases, or strokes due to undetermined cause, cryptogenic strokes, embolic strokes, embolic strokes of undetermined source, or events of thrombotic and/or thromboembolic origin leading to stroke or TIA, and disorders of peripheral arteries, leading to peripheral artery disease, including peripheral artery occlusion, acute limb ischemia, amputation, reocclusions and restenoses after interventions such as angioplasty, stent implantation or surgery and bypass.

~~12~~11. Medicament comprising a compound according to any of Claims 1 to 6 in combination with an inert, nontoxic, pharmaceutically suitable excipient.

~~13~~12. Medicament according to Claim ~~12~~ 11 for use in the treatment and/or prophylaxis of thrombotic or thromboembolic disorders.

~~14~~13. Compound according to any of Claims 1 to 6 for use in a method for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders using a therapeutically effective amount of a compound according to the invention.

~~15. Method for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders in humans and animals by administration of a therapeutically effective amount of at least one compound according to any of Claims 1 to 6, of a medicament according to Claim 12 or of a medicament obtained according to Claim 9 or 10.~~